Product Information
EXELON 13.3 MG/24HR PATCH is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $22.0078 per EA under NDC 00078050315. Its NADAC has been published 548 times since Nov 28, 2013.
FDA first approved this application on Jul 6, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the rivastigmine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
13.3 mg/24h
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078050315
Classification
Brand
Dosage Form
PATCH, EXTENDED RELEASE
Route
TRANSDERMAL
Effective Date
9/17/2025
Active Ingredients
RIVASTIGMINEApproval Type
New Drug (NDA)
FDA Application
NDA022083FDA Approved
7/6/2007
TE Code
AB
On Market Since
7/6/2007
Pharmacological Classes
Price Statistics
The NADAC for EXELON 13.3 MG/24HR PATCH has been published 548 times since Nov 28, 2013, and over the history we have for it it has risen 119.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.0078 per EA |
|---|---|
| All-time high | $22.0078 (Aug 19, 2026) |
| All-time low | $10.0487 (Nov 28, 2013) |
| 52-week high | $22.0078 |
| 52-week low | $21.9769 |
| Median price | $21.8391 |
| Average price | $19.0932 |
| Largest weekly change | +19.9% (Apr 15, 2015) |
| Weeks tracked | 548 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 92% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EXELON 13.3 MG/24HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for EXELON 13.3 MG/24HR PATCH, manufactured by Novartis Pharmaceuticals Corporation, is $22.0078 per EA (NDC 00078050315), effective Aug 19, 2026.
How has the price of EXELON 13.3 MG/24HR PATCH changed over time?
Over the history we have for it, the NADAC for EXELON 13.3 MG/24HR PATCH has risen 119.0%. It has been tracked across 548 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXELON 13.3 MG/24HR PATCH?
Since Nov 28, 2013, the NADAC for EXELON 13.3 MG/24HR PATCH has ranged from a low of $10.0487 (Nov 28, 2013) to a high of $22.0078 (Aug 19, 2026), with a median of $21.8391 per EA.
Are there cheaper alternatives to EXELON 13.3 MG/24HR PATCH?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIVASTIGMINE 13.3 MG/24HR PTCH, is $1.8036 per EA — about 92% below EXELON 13.3 MG/24HR PATCH.
Who manufactures EXELON 13.3 MG/24HR PATCH?
EXELON 13.3 MG/24HR PATCH (NDC 00078050315) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.